ProMIS Neurosciences (PMN) Cash from Financing Activities (2021 - 2026)

ProMIS Neurosciences (PMN) has 5 years of Cash from Financing Activities data on file, last reported at $70.1 million in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $70.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.8 million (changed N/A YoY) and the FY2025 annual result came in at $20.9 million, down 24.86% from the prior year.
• Cash from Financing Activities improved to $70.1 million in Q1 2026, from -$1.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $70.1 million in Q1 2026 to a low of -$510614.0 in Q4 2023.
• A 4-year average of $16.2 million and a median of $330136.5 in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 192.05% — and 2025, when it slumped 100.0%.
• Tracing PMN's Cash from Financing Activities over 4 years: stood at -$510614.0 in 2023, then surged by 192.05% to $469999.0 in 2024, then tumbled by 100.0% to -$1.0 in 2025, then soared by 7008131000.0% to $70.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $70.1 million (Q1 2026), -$1.0 (Q4 2025), and $469999.0 (Q4 2024), per Business Quant data.